The Slow Death of AIA Trials: Inside the USPTO’s Controversial "One-and-Done" PTAB Rule Package

Main Facts

The United States Patent and Trademark Office (USPTO) has sparked a fierce national debate with the publication of a sweeping, aggressive new regulatory package targeting the Patent Trial and Appeal Board (PTAB). At the heart of the controversy is a proposed "one-and-done" rule designed to fundamentally alter how inter partes review (IPR) challenges operate under the Leahy-Smith America Invents Act (AIA).

If enacted in its current form, the rules package will dramatically reshape who can challenge patents, the timeline for doing so, and the systemic weight of prior validity determinations. Under the guise of administrative efficiency and fairness, the rule effectively converts a single favorable patent validity finding—whether from a district court litigation or a USPTO reexamination—into permanent, system-wide protection. This shields the patent from subsequent challenges by future defendants, a concept critics liken to "gold-plating" patents and resurrecting defunct estoppel regimes through executive rulemaking rather than congressional legislation.

The public comment period for this controversial proposal has officially closed, revealing deep fractures within the intellectual property community. The USPTO received more than 10,000 comments from over 700 individual stakeholders, turning the administrative proceeding into a legislative flashpoint. Legal scholars, industry leaders, former lawmakers, and major corporations are openly asking whether the executive branch is attempting de facto legislation to neuter the PTAB, sidestep Congress, and dismantle a foundational pillar of modern patent law.

Chronology of Events

To understand how the PTAB arrived at this precarious crossroads, it is necessary to examine the timeline of administrative rulemaking, legislative stagnation, and shifting executive priorities:

• September 2011: Congress passes the Leahy-Smith America Invents Act (AIA), creating inter partes review (IPR) as a streamlined, cost-effective administrative alternative to district court litigation for challenging patent validity. Crucially, Congress hard-wires a non-appealability clause into the statute, making PTAB institution decisions final and unreviewable by appellate courts.
• 2012–2020: The PTAB rapidly becomes the primary battleground for patent validity disputes. Successive USPTO Directors issue varying guidance, policy memos, and precedential decisions regarding discretionary denials (such as the Fintiv rule), establishing a pattern of executive policy whiplash that leaves stakeholders navigating shifting procedural sands.
• 2024–Early 2025: Amid legislative paralysis in Congress—where major patent bills like the PREVAIL Act and PERA stall repeatedly—the executive branch moves to take matters into its own hands.
• Late 2025: USPTO Director John Squires unveils the aggressive "one-and-done" rules package. The proposal seeks to permanently codify broad administrative estoppel and curtail serial challenges by restricting subsequent defendants from bringing IPR petitions against patents previously upheld in court or via reexamination.
• December 2025: The public comment window for the proposed rules package officially closes, generating an unprecedented volume of over 10,000 comments and sparking fierce public debates, including deep-dive analyses on platforms like IPWatchdog Unleashed featuring PTAB veteran Scott McKeown.

Supporting Data and Stakeholder Engagement

The sheer volume of responses to the USPTO’s proposed rulemaking highlights the profound stakes involved. Quantitative and qualitative metrics from the comment period underscore a deeply polarized ecosystem:

• 10,000+ Comments: An exceptionally high volume of public feedback reflecting intense nationwide interest from diverse economic sectors, including life sciences, high-tech, telecommunications, and manufacturing.
• 700+ Individual Commenters: A broad cross-section of stakeholders—ranging from independent inventors and small-to-medium enterprises (SMEs) to Fortune 500 tech giants and pharmaceutical conglomerates—weighing in on the administrative overreach.
• The "Fairness" vs. "Overreach" Divide: Proponents of the rule emphasize conservation of finite government resources and protection against abusive, serial copy-cat litigation. Conversely, opponents present data and legal arguments showing that the rule eliminates critical error-correction mechanisms, leaving the public vulnerable to weak or improperly granted patents.

Official Responses and Perspectives

The debate over the one-and-done package has aligned current and former officials, legal experts, and industry stakeholders into sharply opposing camps.

The USPTO’s Rationale: Efficiency and Finality

From the perspective of USPTO leadership, the rules package is framed as a matter of basic equity and administrative common sense. Director John Squires’ pitch rests on a straightforward premise: if a patent has already survived a rigorous validity challenge in a district court or a USPTO reexamination, subsequent defendants should not receive an unbounded license to wage endless, serial attacks at the PTAB.

At a macro level, this framing resonates with many observers. The USPTO and the PTAB operate with finite public resources. Forcing the agency to repeatedly review the exact same patent claims against identical prior art—merely because a new corporate entity has entered the litigation—can appear inefficient and wasteful. Proponents argue that true property rights require finality, and a patent owner should not be subjected to perpetual legal probation over the course of a 20-year term.

Criticisms from the Legal Bar and Former Lawmakers

Critics, however, warn that the administration’s "fairness" rhetoric masks a sweeping structural overreach. During a recent episode of IPWatchdog Unleashed, PTAB expert Scott McKeown joined host Gene Quinn to cut through the administrative spin, arguing that the rule goes far beyond preventing localized litigation abuse.

McKeown points out three critical flaws in the USPTO’s approach:

1. System-Wide Gold-Plating: The rule transforms a single win in a localized district court case or an agency reexamination into absolute, system-wide immunity, effectively shielding the patent from all future challenges regardless of new, highly relevant prior art uncovered by other parties.
2. Resurrection of Defunct Estoppel: Congress deliberately dismantled expansive administrative estoppel regimes when it replaced older inter partes reexamination procedures with the streamlined IPR framework under the AIA. Critics argue the USPTO is attempting to rewrite statutory law by executive regulation.
3. Bypassing Congress: Several former Members of Congress who originally authored the AIA have publicly objected to the rules package, declaring that it oversteps statutory boundaries and violates the explicit intent of the legislation they drafted.

Compounding this tension is the structural flaw hard-wired into the AIA: the non-appealability of institution decisions. Because Congress insulated PTAB gate-keeping decisions from judicial review, successive USPTO Directors have enjoyed sweeping discretion. While the Federal Circuit has carved out narrow exceptions for constitutional questions, it generally refuses to second-guess the Director’s substantive policy choices. This vacuum has fostered a volatile "ping-pong" environment where each new administration governs by executive memo—prompting Director Squires to enshrine his policies into formal rules to prevent future reversals.

Implications for the U.S. Patent System and Stakeholders

The fallout from this administrative rulemaking extends far beyond procedural technicalities, threatening profound consequences for the American innovation economy, legislative reform, and the stability of intellectual property rights.

1. The Demise of Major Legislative Reform

For years, patent owners and tech companies have looked to Capitol Hill for structural fixes via legislation such as the PREVAIL Act and the Patent Eligibility Restoration Act (PERA). However, as McKeown and other industry observers note, if the USPTO successfully guts the PTAB and curtails IPR through executive fiat, these legislative efforts will likely be rendered dead on arrival. Lawmakers will see little reason to expend political capital fixing an administrative agency that is actively rewriting its own rules. Ironically, aggressive executive rulemaking starves the legislative branch of the oxygen needed to enact durable, statutory reforms.

2. Guaranteed Litigation and Systemic Instability

Legal challenges to the final rules package are not merely likely—they are an absolute certainty. Patent owners tempted to celebrate any measure that makes life difficult for petitioners should heed a crucial warning: the same administrative apparatus that dismantles IPR by executive memo today can reverse course and destabilize patent owners tomorrow when political winds shift. Introducing years of inevitable federal court litigation over administrative overreach will only inject further chaos into a patent system already struggling to provide reliable, predictable quiet title.

3. Practical Takeaways for Companies

For technology developers, life-sciences firms, and manufacturing enterprises, the message from the current PTAB battleground is sobering. Stakeholders must budget for prolonged legal uncertainty, increased procedural litigation, and ongoing administrative whiplash. While the PTAB is not disappearing, it is being steadily weakened and deeply politicized.

Ultimately, the U.S. patent system requires a comprehensive, first-principles reset of how administrative error-correction functions—not another rushed, politically motivated administrative coup. Until Congress heals its deep legislative dysfunction and reasserts its constitutional role, the patent system will remain suspended in a precarious cycle of executive rulemaking, judicial friction, and perpetual instability.

Disclaimer: The analyses and discussions presented in this article do not constitute legal advice, nor do they establish an attorney-client relationship. The views expressed reflect commentary on ongoing administrative proceedings and should not be attributed to individual employers or organizational sponsors.